How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention
- 17 October 2018
- journal article
- review article
- Published by Springer Nature in Current Cardiology Reports
- Vol. 20 (12) , 1-7
Abstract
Purpose of the Review To summarize advances in genomic medicine and anticipated future directions to improve cardiovascular risk reduction. Recent Findings Mendelian randomization and genome-wide association studies have given significant insights into the role of genetics in dyslipidemia and cardiovascular disease (CVD), with over 160 gene loci found to be associated with coronary artery disease to date. This has enabled the creation of genetic risk scores that have demonstrated improved risk prediction when added to clinical markers of CVD risk. Summary Incorporation of genomic data into clinical patient care is on the horizon. Genomic medicine is expected to offer improved risk assessment, determination of targeted treatment strategies, and improved detection of lipid disorders causal to CVD development.Keywords
This publication has 58 references indexed in Scilit:
- Discovery and refinement of loci associated with lipid levelsNature Genetics, 2013
- Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trialGene Therapy, 2012
- Excess of Rare Variants in Non–Genome-Wide Association Study Candidate Genes in Patients With HypertriglyceridemiaCirculation: Cardiovascular Genetics, 2012
- Five Years of GWAS DiscoveryThe American Journal of Human Genetics, 2012
- Association of Genetic Variants and Incident Coronary Heart Disease in Multiethnic CohortsCirculation: Cardiovascular Genetics, 2011
- An Increased Burden of Common and Rare Lipid-Associated Risk Alleles Contributes to the Phenotypic Spectrum of HypertriglyceridemiaArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Genetic Risk Score and Risk of Myocardial Infarction in HispanicsCirculation, 2011
- Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in miceNature, 2010
- Hypertriglyceridemia: phenomics and genomicsMolecular and Cellular Biochemistry, 2009
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003